Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


SHP2(WT)@pLKO-Trex-SBP Citations (1)

Originally described in: Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao HX, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang JH, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, Fortin PD Nature. 2016 Jul 7;535(7610):148-52.
PubMed Journal

Articles Citing SHP2(WT)@pLKO-Trex-SBP

The YAP-Interacting Phosphatase SHP2 can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma. Buckarma EH, Werneburg NW, Conboy CB, Kabashima A, O'Brien DR, Wang C, Rizvi S, Smoot RL. Mol Cancer Res. 2020 Jul 9. pii: 1541-7786.MCR-20-0165. doi: 10.1158/1541-7786.MCR-20-0165. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.